UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)
Cell Therapeutics, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
150934107
(CUSIP Number)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[X] Rule 13d-1(b)
[_] Rule 13d-1(c)
[_] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
13G
CUSIP NO. 150934107
1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Wells Fargo & Company
Tax Identification No. 41-0449260
2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [_]
(b) [_]
3) SEC USE ONLY
4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF (5) SOLE VOTING POWER
SHARES
BENEFICIALLY (6) SHARED VOTING POWER
OWNED BY
EACH (7) SOLE DISPOSITIVE POWER
REPORTING
PERSON (8) SHARED DISPOSITIVE POWER
WITH
9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10) CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
Less than 5%
12) TYPE OF REPORTING PERSON
HC
2
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)
DISCLAIMER: Information in this Schedule 13G is provided solely for the purpose
of complying with Sections 13(d) and 13(g) of the Act and regulations
promulgated thereunder, and is not to be construed as an admission that Wells
Fargo & Company or any of its subsidiaries is the beneficial owner of the
securities covered by this Schedule 13G for any purpose whatsoever.
Item 1(a) Name of Issuer:
Cell Therapeutics, Inc.
Item 1(b) Address of Issuer's Principal Executive Offices:
501 Elliott Avenue West, Suite 400
Seattle, WA 98119
Item 2(a) Name of Person Filing:
Wells Fargo & Company
Item 2(b) Address of Principal Business Office:
420 Montgomery Street
San Francisco, CA 94104
Item 2(c) Citizenship:
Delaware
Item 2(d) Title of Class of Securities:
Common Stock
Item 2(e) CUSIP Number:
150934107
Item 3 The person filing is a parent holding company in accordance
with 240.13d-1(b)(1)(ii)(G)
Item 4 Ownership:
See Items 5-11 of the cover page. Information as of December 31,
2003.
Item 5 Ownership of Five Percent or Less of a Class:
If this statement is being filed to report the fact that as of the
date hereof the reporting persons have ceased to be beneficial owners
of more than five percent of the class of securities, check the
following [X].
5
Item 6 Ownership of More than Five Percent on Behalf of Another
Person:
Not applicable.
Item 7 Identification and Classification of the Subsidiary Which Acquired
the Security Being Reported on by the Parent Holding Company:
See Attachment A.
Item 8 Identification and Classification of Members of the Group:
Not applicable.
Item 9 Notice of Dissolution of Group:
Not applicable.
Item 10 Certification:
By signing below, I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired in the
ordinary course of business and were not acquired for the purpose of
and do not have the effect of changing or influencing the control of
the issuer of such securities and were not acquired in connection
with or as a participant in any transaction having such purposes or
effect.
Signature.
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete, and correct.
Date: February 2, 2004
WELLS FARGO & COMPANY
By: /s/ Laurel A. Holschuh
----------------------------------------------------------------------
Laurel A. Holschuh, Senior Vice President
and Secretary
4
ATTACHMENT A
The Schedule 13G to which this attachment is appended is filed by Wells Fargo &
Company on behalf of the following subsidiaries:
Peregrine Capital Management, Inc. (1)
Wells Capital Management Incorporated (1)
Wells Fargo Bank, National Association (2)
Wells Fargo Bank Minnesota, National Association (2)
Wells Fargo Investments, LLC (1)(2)
------------------
(1) Classified as a registered investment advisor in accordance with Regulation
13d-1(b)(1)(ii)(E).
(2) Classified as a bank in accordance with Regulation 13d-1(b)(1)(ii)(B).
(3) Classified as a broker dealer in accordance with Regulation
13d-1(b)(1)(ii)(A).
5